Non pharmacological Modulation of Neurotransmitters
- Brief Review of Neurochemistry
- Biochemical Basis of Psychiatric Disease
- Non pharmacological Interventions
Non pharmacological Modulation of Neurotransmitters Brief Review - - PowerPoint PPT Presentation
Non pharmacological Modulation of Neurotransmitters Brief Review of Neurochemistry Biochemical Basis of Psychiatric Disease Non pharmacological Interventions J.Lombard@Genomind.com Neurobehavioral Disorders: How common are
www.nimh.nih.gov
cause of disability in the U.S. and Canada for ages 15 - 44
26.2 percent of Americans ages 18 and older, suffer from a diagnosable mental disorder in a given year (57.7 million people)
serious mental illness
Depressive symptoms (QIDS-SR score) after up to 12 wks antidepressant treatment
3
Huang Dee Nai-Chan. 2600 BC; 1st Chinese Medical Text.
Antonijevic, IA Psychoneuroendocrinology (2006), 31 1-15
Nigrostriatal Pathway Mesolimbic Pathway Substantia nigra Ventral tegmental area Mesocortical Pathway
Brain Behavior Center
pg20
p < 0.002
Control Obese
BMI
p = 0.3
Wang et al, Lancet 2001
Folic Acid 10-formyl-THF Dihydrofolate 5,10-methyenyl-THF 5,10-methylene-THF Tetrahydrofolate L-methylfolate
SHMT
L-methylfolate
Cell Membrane
L-methylfolate
DHFR MTHFD1 MTHFD1 MTHFD1 DHFR RFC1
Methionine SAMe SAH Homocysteine
DNA Methylated DNA, RNA, protein, lipids MTHFR BH4 BH2 Tryptophan Tyrosine
Serotonin Dopamine Norepinephrine
MTHFR
26
with the transporter protein
with ADHD.
modulates transporter function, suggesting that response to stimulants is reduced in zinc-deficient ADHD patients. zinc supplementation in zinc-deficient ADHD patients improves the binding status of insufficiently occupied zinc binding sites on the dopamine transporter.
hyperactivity disorder in children: a double blind and randomized trial
sulfate in the treatment of attention deficit hyperactivity disorder.
J Affect Disord. 2012 Jan;136(1-2):e31-9. Epub 2011 Jul 27.
COMT Polymorphisms Effect Possible Clinical Significance
Val/Val
COMT Rapid degradation DA , Impact on working memory
Val/Met
Wild type
Met/Met
COMT Slow degradation catacholamines, estrogen and metabolites Impact on Addiction, pain Impact if family risk to breast cancer
Catechol-O-methyltransferase (COMT) is the enzyme responsible for degrading dopamine, norepinephrine and estrogen.
demonstrated approx 6 point reduction on HAM- D depression scores
plays critical role in methylation and synthesis of catecholamines
reduced brain bionergetic status; SAMe may exert antidepressant effects by increased creatine and ATP
guanidinoacetic acid (GAA) to produce creatine
standard antidepressants
supsected
stability are issues
common than overt hypothyroid in elderly, especially women
normal T, (other values: T3 and rT3 values)
predisposing factor for depression,
Davis JD et al: Current Psychiatry Reports (2003)S:384-390,Biondi B et al; Endocrine Rev 2008;20(1):76-131
Increased risk for weight gain and metabolic syndrome with Atypical Antipsychotics
Mediates satiety signaling in the hypothalamus Use caution when prescribing Atypical Antipsychotics Consider therapies that reduce weight gain
37
38
VM nucleus regulates satiety
Channels cycle between open and closed conformations. When open, a channel provides a continuous pathway through the bilayer, allowing flux of many ions. Calcium channels are examples of a channel.
closed conformation change
45
47
49
(Psychopharmacology 2006. Jan 254-6); Reduction of self injurious behavior (J Clinical Psychiatry Nov 05,1494-97) and Autism (publication pending)
“We found genes involved in learning and memory were among those most significantly reduced in the aging human brain.” Other glitches appear in a set of genes that regulate energy protection and transport
Some of these alterations show up in people as young as their 40s.”
Harvard Gazette, June 17, 2004
Jost BC, Grossberg GT. J Am Geriatr Soc. 1996;44:1078-1081. Agitation Diurnal Rhythm Irritability Wandering Aggression Hallucinations Mood Change Socially Unacceptable Delusions Sexually Inappropriate Accusatory Suicidal Ideation Paranoia Depression
100 80 60 40 20 –40 –30 –20 –10 10 20 30
Months Before Diagnosis Months After Diagnosis Prevalence (% of patients)
Anxiety Social Withdrawal
55
(de la Monte et al. J AlzDis 2006; 10:89-109)
Higher adherence to the MeDi is associated with a trend for reduced risk of developing MCI and with reduced risk of MCI conversion to AD.
Scarmeas et Arch Neurol. 2009 Feb;66(2):216-25l. Arch Neurol. 2009 Feb; 66(2):216-225.
zinc
and fatigue
genotype- S adenosylmethionine
channel genotype variants- Omega 3 fish oil, magnesium, vitamin D